Literature DB >> 21333908

Therapies aimed at the gut microbiota and inflammation: antibiotics, prebiotics, probiotics, synbiotics, anti-inflammatory therapies.

Eamonn M M Quigley1.   

Abstract

Several recent observations have raised the possibility that disturbances in the gut microbiota and/or a low-grade inflammatory state may contribute to symptomatology and the etiology of irritable bowel syndrome (IBS). Consequent on these hypotheses, several therapeutic categories have found their way into the armamentarium of those who care for IBS sufferers. These agents include probiotics, prebiotics, antibiotics, and anti-inflammatory agents.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21333908     DOI： 10.1016/j.gtc.2010.12.009

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN： 0889-8553            Impact factor:   3.806


  19 in total

Review 1.  Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.

Authors:  Eleonora Distrutti; Lorenzo Monaldi; Patrizia Ricci; Stefano Fiorucci
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

2.  Bifidobacteria isolated from infants and cultured on human milk oligosaccharides affect intestinal epithelial function.

Authors:  Maciej Chichlowski; Guillaume De Lartigue; J Bruce German; Helen E Raybould; David A Mills
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-09       Impact factor: 2.839

Review 3.  The microbiota link to irritable bowel syndrome: an emerging story.

Authors:  Ian B Jeffery; Eamonn M M Quigley; Lena Öhman; Magnus Simrén; Paul W O'Toole
Journal:  Gut Microbes       Date:  2012-08-16

Review 4.  The role of the microbiome in rheumatic diseases.

Authors:  Nigel Yeoh; Jeremy P Burton; Praema Suppiah; Gregor Reid; Simon Stebbings
Journal:  Curr Rheumatol Rep       Date:  2013-03       Impact factor: 4.592

Review 5.  Microbiota-host interactions in irritable bowel syndrome: epithelial barrier, immune regulation and brain-gut interactions.

Authors:  Niall P Hyland; Eamonn M M Quigley; Elizabeth Brint
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

Review 6.  The microbiome and psoriatic arthritis.

Authors:  Hester Eppinga; Sergey R Konstantinov; Maikel P Peppelenbosch; H Bing Thio
Journal:  Curr Rheumatol Rep       Date:  2014-03       Impact factor: 4.592

7.  Intestinal microbiota in functional bowel disorders: a Rome foundation report.

Authors:  Magnus Simrén; Giovanni Barbara; Harry J Flint; Brennan M R Spiegel; Robin C Spiller; Stephen Vanner; Elena F Verdu; Peter J Whorwell; Erwin G Zoetendal
Journal:  Gut       Date:  2012-06-22       Impact factor: 23.059

8.  Glutamate Transporter GLT-1 Upregulation Attenuates Visceral Nociception and Hyperalgesia via Spinal Mechanisms Not Related to Anti-Inflammatory or Probiotic Effects.

Authors:  Y Lin; K Roman; K D Foust; B K Kaspar; M T Bailey; R L Stephens
Journal:  Pain Res Treat       Date:  2011-12-12

Review 9.  Diet-microbiota interactions and their implications for healthy living.

Authors:  Ian B Jeffery; Paul W O'Toole
Journal:  Nutrients       Date:  2013-01-17       Impact factor: 5.717

10.  A randomised controlled trial of a probiotic 'functional food' in the management of irritable bowel syndrome.

Authors:  Lesley M Roberts; Deborah McCahon; Roger Holder; Sue Wilson; F D Richard Hobbs
Journal:  BMC Gastroenterol       Date:  2013-03-07       Impact factor: 3.067
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.